Gastroenterology Department, Centro Hospitalar do Alto Ave, Guimarães, Portugal.
BioDrugs. 2010 Dec 14;24 Suppl 1:37-9. doi: 10.2165/11586220-000000000-00000.
In patients with inflammatory bowel disease (IBD) the prevalence of ankylosing spondylitis is 4-10%, and approximately 5-10% of ankylosing spondylitis patients have concomitant IBD. The correct recognition of spondyloarthritides is essential in order to identify common therapeutic strategies, especially in the era of new biological therapies such as infliximab. This paper reports a case of a patient with a severe presentation of ankylosing spondylitis and Crohn's disease successfully treated with infliximab. Two important points concerning this case are discussed: one is the true value of non-steroidal anti-inflammatory drug-induced IBD exacerbation and the other is the role of anti-tumor necrosis factor agents (especially infliximab) in the treatment of patients with concomitant diseases.
在炎症性肠病（IBD）患者中，强直性脊柱炎的患病率为 4-10%，而大约 5-10%的强直性脊柱炎患者同时患有 IBD。正确识别脊柱关节炎对于确定共同的治疗策略至关重要，特别是在新型生物治疗（如英夫利昔单抗）时代。本文报告了一例严重强直性脊柱炎和克罗恩病患者成功接受英夫利昔单抗治疗的病例。本文讨论了该病例的两个重要问题：一个是非甾体抗炎药诱导的 IBD 加重的真正价值，另一个是抗肿瘤坏死因子药物（尤其是英夫利昔单抗）在合并疾病患者治疗中的作用。
